文献速递精神分裂症与精神病性障碍心境障碍老年精神

脑穿透性钙通道阻滞剂与神经精神疾病发病率降低相关

Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.
PubMed 文献 · Mol Psychiatry · 2022-05-26

研究利用TriNetX电子健康记录,比较脑穿透性钙通道阻滞剂(BP-CCB)与低脑穿透性氨氯地平使用者的神经精神疾病发病率。在无精神疾病史者中,BP-CCB组多数疾病发病率显著较低,总体风险比0.88,即风险降低12%。在有既往诊断者中差异较小,但BP-CCB组几种疾病风险仍较低。

要点

  • 无精神疾病史者中,BP-CCB组多数神经精神疾病发病率显著低于氨氯地平组,总体风险比0.88。
  • 有既往精神或神经退行性疾病诊断者中,BP-CCB与氨氯地平差异较小,但BP-CCB组几种疾病风险仍较低。
  • 与血管紧张素受体阻滞剂相比,BP-CCB总体风险比0.94,但不同疾病方向不一。

核心结论

  • 易穿透大脑的钙通道阻滞剂相比不穿透者与较低的神经精神疾病发病率相关,尤其首次诊断。

研究设计与样本

  • 利用TriNetX电子健康记录网络识别使用脑穿透性CCB或氨氯地平的患者,构建有无特定ICD-10诊断的队列,倾向评分匹配年龄、性别、种族、血压、BMI等变量,匹配队列大小17,896至49,987,结局为两年暴露期内的发病率。

主要发现

  • 无既往精神或神经退行性疾病史者中,BP-CCB组多数疾病发病率显著低于氨氯地平组,风险比0.64至0.88,总体风险比0.88(风险降低12%)。
  • 有既往精神或神经退行性疾病诊断者中,BP-CCB与氨氯地平差异较小,但BP-CCB组几种疾病风险仍较低。
  • 女性及60岁以下人群中差异更明显。
  • BP-CCB与维拉帕米或地尔硫䓬比较结果相似。
  • BP-CCB与血管紧张素受体阻滞剂比较总体风险比0.94,但精神障碍和痴呆风险较高,焦虑和睡眠障碍风险较低。

关键数值与推荐

  • 无既往史者中BP-CCB vs 氨氯地平的风险比范围0.64至0.88,总体风险比0.88(风险降低12%)。
  • BP-CCB vs 血管紧张素受体阻滞剂总体风险比0.94。

临床怎么用

  • 原文未报告临床实践建议。

局限性

  • 部分分析中,即使经过广泛匹配,阴性对照结局仍显示BP-CCB组发病率低于对照队列,提示存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calcium channel blockers (CCBs) differ in their ability to penetrate into the brain. Pharmacoepidemiological studies suggest that CCBs as a class may have beneficial effects on the risks and outcomes of some psychiatric and neurological disorders. It is plausible but unknown whether this effect relates to their brain penetrance. To address this, we used the TriNetX electronic health records network to identify people prescribed a brain-penetrant CCB (BP-CCB), or those given amlodipine, a CCB with low brain penetrability. We created cohorts of patients who, prior to first CCB exposure, either had to have, or could not have had, a recorded ICD-10 diagnosis in any of the following categories: psychotic disorder; affective disorder (including bipolar disorder and major depressive disorder); anxiety disorder; substance use disorder; sleep disorder; delirium; dementia, or movement disorder. Cohort pairs were propensity score matched for age, sex, race, blood pressure, body mass index, and a range of other variables. The outcomes were the incidence of these disorders measured over a two-year exposure period. Matched cohort sizes ranged from 17,896 to 49,987. In people with no prior history of psychiatric or neurodegenerative disorder, there was a significantly lower incidence of most disorders with BP-CCBs compared to amlodipine, with risk ratios ranging from 0.64 to 0.88 and an overall risk ratio of 0.88, i.e. a risk reduction of 12%. In people who did have a prior psychiatric or neurodegenerative diagnosis, differences were much smaller, but again showed lower risks for several disorders with BP-CCBs compared to amlodipine. The differences were somewhat more marked in women and in people less than 60 years old. Results were similar when comparing BP-CCBs with verapamil and diltiazem. We also compared BP-CCBs with angiotensin receptor blockers, and found an overall risk ratio of 0.94 in favour of BP-CCBs, but with differential effects across disorders including a higher risk of psychotic disorder and dementia, but a lower risk for anxiety and sleep disorders. In some analyses, there was evidence of residual confounding even after the extensive matching, in that negative control outcomes showed a reduced incidence with BP-CCBs relative to the comparator cohort. In summary, CCBs that readily penetrate the brain are associated with a lower incidence of neuropsychiatric disorders, especially first diagnoses, compared to CCBs which do not. This may reflect their blockade of neuronal voltage-gated calcium channels. The findings encourage repurposing trials using existing BP-CCBs, and suggest that novel BP-CCBs with enhanced and more selective central actions might have greater therapeutic potential for psychiatric and neurodegenerative disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Colbourne L, Harrison PJ. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Mol Psychiatry. 2022. PMID: 35618884. doi:10.1038/s41380-022-01615-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。